Development code · Small Molecule
STX209
STX209 is a development code for Arbaclofen, developed by Seaside Therapeutics, Inc..
- Status
- Phase 2 for Autism spectrum disorder
- Mechanism
- GABA-B receptor Agonist
- Developer
- Seaside Therapeutics, Inc.
Programs
- Arbaclofen for Autism spectrum disorderPhase 2Active
- Arbaclofen for Fragile X syndromePhase 3Active
- Arbaclofen for Multiple sclerosisPhase 3Unknown
Also known as
- STX-209
- arbaclofen
- R-baclofen
- (R)-baclofen
- OS440
- 69308-37-8
- (3R)-4-amino-3-(4-chlorophenyl)butanoic acid